InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,220.00
(
-0.20%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.39
(
0.00%
)
Bitcoin
64,330.14
(
0.13%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DonShimoda

Send PM Follow Ignore
Followers 19
Posts 727
Boards Moderated 0
Alias Born 11/10/2009

DonShimoda

Re: biotech_researcher post# 5250

Monday, 01/24/2011 10:07:00 AM

Monday, January 24, 2011 10:07:00 AM

Post# of 80490
sorry about that, here's a repost of the potential catalysts that are most likely to affect ARIA in 2011:

Ponatinib partnering in Asia and/or EU
Start of AP113 Phase 1 trial
New Phase 3 ridaforolimus trials (P3 endometrial-single agent? P2 breast in combination with Merck's IGFR1 inhibitor, dalotuzumab??)
ASCO - first detailed look at SUCCEED data
possible first look at ponatinib data at ASH?
Ponatinib full enrollment
Filing rida NDA
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up